Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOOSE study of dostarlimab for fertility-sparing treatment in MMR-deficient endometrial cancer
2023-509535-11-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in endometrial cancer (EC) and endometrioid adenocarcinoma, sponsored by UZ Leuven. Primary endpoint: Complete response rate. Planned start Sep 2026; status: authorised.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)endometrioid adenocarcinoma
Beyond the preview
Go deeper on 2023-509535-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509535-11-00.